SEC Filings
Rhythm Owes LG Chem $350 Million Over Four Years, Backed By A $750 Million Loan Only $250 Million Funded
Rhythm Pharmaceuticals will pay to cut a bivamelagon royalty to 1%, while two later loan tranches depend on conditions or lender consent.